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We examined the effect of population-based screening programme on tumour characteristics by comparing carcinomas diagnosed
during the prescreening (N¼341) and screening (N¼552) periods. We identified screen detected (N¼224), interval (N¼99) and
clinical cancer (N¼229) cases. Median tumour size and proportion of axillary lymph node negative cases were 1.5cm and 65% in the
screen detected group, 2.0cm and 44% in cases found outside the screening, and 3.2cm and 41% in the cases from the prescreening
period. Survival of the breast cancer patients was 66% (95% CI, 60–71%) in the prescreening era group and 73% (95% CI, 66–78%)
in the screening era group after 10 years of follow-up. In the screening era group the survival of the screen detected cases was 86%
(95% CI, 80–90%) and that of the clinical cancer cases 73% (95% CI, 66–78%) after 10 years. In multivariate analysis the risk of breast
cancer death was not significantly different between the prescreening and screening periods (HR 0.82; 95% CI 0.59–1.12, P¼0.21).
Detection by screening was not an independent prognostic factor in multivariate analysis (HR 0.75; CI 95% 0.50–1.12; P¼0.17).
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Mammography service screening programmes have been intro-
duced in more than 20 countries (Shapiro et al, 1998). Several
guidelines and different expert groups recommend mammography
screening examinations (IARC, 2002) despite the contradicting
opinions questioning the positive effect of the screening (Gotzsche
and Olsen, 2000). Recent evaluations have shown that service
screening may be even more effective than screening in popula-
tion-based trials (Duffy et al, 2002; Paci et al, 2002; Gorini et al,
2004). Information of actual participation to screening, data of
incident cancers and detailed information of tumour character-
istics have provided more precise information of breast cancer
prognosis in the screened and not-screened patients (Ernst et al,
2004). Comparison of incident-based breast cancer mortality
before and after beginning of screening has shown a significant
mortality reduction (Tabar et al, 2003; Gorini et al, 2004).
It has been shown that a shift to smaller tumour size has
occurred after introduction of mammography screening (Kricker
et al, 1999; Tabar et al, 2003). The studies reporting the
significance of mammography screening as an independent
prognosticator of survival are contradictory. Screening as a mode
of cancer detection was not an independent factor in a study by
Klemi et al (2003). In contrast to this finding, a recent multicentre
study reported that screening itself had an independent role in
prognostication of distant recurrences of breast cancer (Joensuu
et al, 2004). Gill et al (2004) also found that detection by screening
was a powerful independent prognosticator.
There are only few works combining data of individual
screening history, survival and hospital patient records. In this
work, we present a population-based breast cancer material from a
Finnish health care district and compare eras before service
screening (1977–1986) and during screening (1987–1997). Ana-
lyses based on incident breast cancers of women aged 50–69 years
focus in finding differences in survival between cancer groups with
different modes of detection.
MATERIAL AND METHODS
Patients
Health Care District of Central Finland is a defined geographical
and administrative area in Central Finland around the city of
Jyva ¨skyla ¨. The average population of the district is about 260000
and the number of women aged 50–69 years is about 28500. In
this study, we identified two groups of patients aged 50–69 years,
one represented a prescreening era (years 1977–1986) and the
other represented an era during a service screening (years 1987–
1997, screening era group). According to the files of Finnish
Cancer Registry and patient files of Health Care District the
numbers of new breast cancer cases were 341 in the prescreening
era group and 552 in the screening era group.
Most of the patients were operated in two hospitals of the area:
Jyva ¨skyla ¨ Central Hospital in Jyva ¨skyla ¨ and Jokilaakso Hospital in
Ja ¨msa ¨. Surgical and oncologic data and pathology reports were
collected from patient files in 759 (85%) cases. Patient records
were no longer available in 36 (4%) cases and 98 (11%) women
were treated outside the Health Care District. Only invasive
cancers were included in the study.
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Finnish Cancer Registry and Governmental Statistics Finland.
Both registers utilise Finnish national social security code, which
enables precise person identification. Survival data and detailed
information of the causes of death were available at individual
patient level in all cases. Follow-up was closed on June 2003.
Median follow-up time was 12.5 years (range, 0.1–26.4 years) in
the prescreening era group and 8.0 years (range, 0.1–16.4 years) in
the screening era group.
In most cases the largest tumour diameter was recorded from
pathology reports. If histological diameter was not available
the tumour diameter was extracted from surgical files. Mammo-
graphy reports of tumour size were not used. Tumour diameter
was missing in 89 (10%) cases, 61 (18%) of these belonged to
the prescreening era group and 28 (8%) to the screening era
group.
The lymph node status was unknown in 134 cases (15%).
Pathology reports of the prescreening era did not state the total
number of investigated or affected lymph nodes. The axillary
lymph node status was also classified only as positive or negative
in 71 cases in the screening era group. The axillary dissection was
omitted in 20 cases treated in Jyva ¨skyla ¨ Central Hospital.
Staging was performed according to the TNM system of the
International Union against Cancer (Sobin and Witekind, 2002).
Screening
Population-based breast cancer service screening started in Central
Finland in 1987. Women aged 50–69 were invited by a personal
letter to the screening. Two-view mammography was performed
and read by two specially trained radiologists every 2 years
according to a detailed programme. The programme was
recommended by the National Board of Health (Hakama et al,
1991). First screening round was completed in 1991.
Women invited to screening were identified for the present
study from the registers of Cancer Society of Central Finland,
which actually organised the screening. During the first years of
screening (1987–1990) no computer-based databases were avail-
able. However, data of all positive screening results was registered
and was available for this study. Computerised data of attendance
and results of all screening examinations were recorded from the
beginning of 1991 onwards. During the screening era (1987–1997)
30251 women were invited to screening and 22499 attended.
Attendance rate was 79% at the age-group 50–59 years and 58% at
the group 60–69 years. In the whole material, the attendance rate
was 71%. In the screening era group, the proportion of women at
the age of 60–69 years was lower compared to the prescreening
era, because of low attendance rate (58%) in this age group.
Altogether 59817 screening examinations were made. There were
2.5 screening visits in average per woman. Annual call-back rate
was between 1.6 and 4.8%.
Altogether 224 incident breast cancers were found at service
screening (screen-detected cases) during the years 1987–97.
Interval cancers were identified by comparing the files of Finnish
Cancer Registry and the screening register of Cancer Society of
Central Finland. Breast cancer was classified as an interval cancer
if a new incident cancer occurred after negative screening during
the following 2 years. Altogether 99 interval cancers were
identified.
There were 169 breast cancer patients in the screening era
group who never attended the screening examination before their
breast cancer diagnosis (never attenders). If the cancer diagnosis
was made more than 2 years after the latest screening exami-
nation the case was classified as a partial attender. This
group consisted of 60 women. The groups of never attenders and
partial attenders together were classified as clinical cancers
(N¼229).
STATISTICAL METHODS
The results were expressed as median and interquartile range
(IQR). Statistical comparison was made by using Mann–Whitney
U-test. Measures with a discrete distribution are expressed as
counts (%) and analysed by w
2 or Fischer–Freeman–Halton test.
Kaplan–Meier curves were used to illustrate information on the
cumulative proportions of survival groups tested by using log-rank
methods. The prognostic factors predicting the duration of the
survival time were analysed using univariate and multivariate
proportional hazard regression models, called Cox’s regression
models.
RESULTS
Tumour characteristics
There was a significant change to a more favourable stage
distribution during the study period from the prescreening era
to the screening era. The proportion of stage I cases increased from
14 to 36% and the proportion of stage III cases decreased from
15 to 4%. The number of small tumours (p2cm, T1) was clearly
larger in the screening era group (54%) than in the prescreening
(21%) era group (Table 1). Median tumour diameter was 1.8cm in
the screening era group (IQR 1.2, 2.5) and 3.2cm (IQR 2.0, 4.0) in
the prescreening era group (Po0.001).
There were significant differences in stage and tumour
characteristics also in the screening era group. The proportions
of stage I cases and small tumours (T1) were clearly larger in the
screen-detected group than in the group of clinical cancers
(Table 2). Median tumour diameter was 1.5cm (IQR 1.0, 2.0) in
the screen-detected group and 2.0cm (IQR 1.4, 3.0) in the clinical
and interval cancer groups (Po0.001).
Table 1 Characteristics of the prescreening (1977–1986) and screening
era (1987–1997) breast cancers patients (N¼893)
Period
Characteristic
1977–1986
N¼341
1987–1997
N¼552 P-value
Age (years) 0.066
50–59, n (%) 185 (54) 334 (60)
60–69, n (%) 156 (46) 218 (40)
Stage, n (%) o0.001
I 46 (14) 198 (36)
II 157 (46) 274 (50)
III 51 (15) 20 (4)
Unknown 87 (25) 59 (10)
Extend of tumour (T), n
(%)
o0.001
T1 70 (21) 299 (54)
T2 154 (45) 201 (36)
T3 56 (16) 21 (4)
T4 0 (0) 5 (1)
Tx 61 (18) 26 (5)
Pathologic lymph node
status (pN), n (%)
o0.001
pN  140 (41) 289 (52)
pN+ 124 (36) 206 (38)
pX (unknown) 77 (23) 57 (10)
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Screening found 224 (41%) cases of the total number of 552
invasive breast cancers in the screening era group. The proportion
of the screen-detected cancers was 50% in the age group of 50–59
years and 27% in the group of 60–69 years. Interval cancers
represented 18% of all the carcinomas and 31% of the cancers
in the patients who participated the screening examination.
The proportion of interval cancers was 1.7/10000 screening
examinations.
Survival
Survival of the breast cancer patients was 66% (95% CI, 60–71%)
in the prescreening era group and 73% (95%CI, 66–78%) in the
screening era group after 10 years of follow-up. After 5 years there
was no significant difference in survival between the prescreening
era cases and the clinical and interval cancer cases of the screening
era period (Figure 1). In the screening era groups there was a
significant (Po0.001) difference in survival between the screen
detected (86%; 95% CI, 80–90%), interval (79%; 95% CI, 66–88%)
and the clinical cancer cases (73%; 95% CI, 66–78%) after 10
years. Corresponding age adjusted significance was P¼0.0036
(Figure 2).
When comparing crude hazard ratios of interval and screen
detected cancers to clinical cancers the risk of interval cancers was
of borderline significance (P¼0.06; HR 0.58, CI 95%, 0.34–1.02)
and the risk of screen-detected cancers was significantly lower
(Po0.001; HR 0.41, CI 95%, 0.27–0.62). The hazard ratio of
interval cancers did not differ significantly from screen-detected
cancers (P¼0.22; HR 1.47, CI 95%, 0.80–2.70) after adjustment by
age. In multivariate analysis the risks of interval (P¼0.69; HR 0.88,
CI 95%, 0.48–1.62) and screen-detected cancers (P¼0.32; HR 0.77,
CI 95%, 0.46–1.29) were not lower when compared to clinical
cancers after adjustment by age, stage, size and node status.
There was no significant difference in the risk of breast cancer
death (P¼0.21; HR 0.82, CI 95%, 0.59–1.12) between the
screening era and the prescreening era groups after adjustment
for tumour stage, diameter and lymph node status (Table 3).
Tumour detection by screening had no independent prognostic
value after corresponding adjustment (P¼0.17; HR 0.75, CI 95%
0.50–1.12).
DISCUSSION
In this study, we collected a population-based breast cancer
material of 50–69 years old women from periods before and after
Table 2 Characteristics of the screening era (1987–1997) breast cancer patients (N¼552)
Mode of detection
Characteristic Screening N¼224 Interval N¼99 Clinical N¼229 P-value
Age (years)
50–59, n (%) 166 (74) 74 (75) 94 (41) o0.001
60–69, n (%) 58 (26) 25 (25) 135 (59)
Stage, n (%) o0.001
I 111 (50) 30 (30) 57 (25)
II 91 (40) 59 (60) 124 (54)
III 1 (o1) 4 (4) 16 (7)
Unknown 21 (9) 6 (6) 32 (14)
Extend of tumour (T), n (%) o0.001
T1 150 (67) 50 (51) 99 (44)
T2 67 (30) 42 (42) 92 (40)
T3 2 (o1) 3 (3) 16 (7)
T4 0 (0) 2 (2) 3 (1)
Tx (unknown) 5 (2) 2 (2) 19 (8)
Number of axillary metastatic lymph nodes pN0–3, n(%) o0.001
pN0 ( 0 nodes) 145(65) 47(48) 97(42)
pN1 (1–3 nodes) 37(16) 31(31) 47(21)
pN2 (4–9 nodes) 16(7) 12(12) 32(14)
pN3 ( 410 nodes) 2(1) 3(3) 10(4)
pNx (number of nodes unknown) 24(11) 6(6) 43(19)
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Figure 1 Breast cancer survival of patients with screen detected cancers
(N¼224), clinical and interval cancers (N¼328), and prescreening period
cancers (N¼341).
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tumour size and axillary lymph node status all predicted a
considerably more favourable prognosis in the screening era group
than in the cases diagnosed before the onset of screening. The
proportion of stage III cancers reduced from 15% in the
prescreening era to 4% in the screening era cases. As expected,
we also found that screening detected smaller tumours with more
favourable prognosis compared to the clinically detected cancers
of the same era (Fracheboud et al, 2004). In the screen-detected
group, half of the cases were stage I tumours and the proportion of
stage III cases was almost nil. These findings are well in line with
earlier studies showing that there will be a reduction of advanced
tumour stages and increase of more favourable low stage tumours
after several years of ongoing screening (McCann et al, 1998).
Our findings could not confirm the results of two recent studies
reporting that screening itself as a mode of detection has an
independent prognostic role (Gill et al, 2004; Joensuu et al, 2004).
In agreement with our study Klemi et al (2003) reported earlier
that they did not find any association between favourable
prognosis and screening examination itself. These discrepancies
may result from different set-ups of the studies. Our work and the
study of Klemi et al (2003) are based on a material from a single
screening centre which actually carried out the screening and
maintained its own screening register and patient files. In a
retrospective multicentre material of Joensuu et al (2004) there was
a marked difference between hospital and screening register
records. Only 70% of the breast cancer patients treated in the
participating hospitals could be identified in the screening records.
Multicentre materials may also contain larger measurement
variation than data collected from a single institution.
False negative screening results and incidence of interval cancers
have an important influence on the success of breast cancer
screening programmes. Identification and classification of the
interval cases also have an effect on estimation of survival
differences between different patient groups. We paid special
attention to finding all the women who got a breast cancer
diagnosis within 2 years after a negative screening examination.
The proportion of interval cancers (31% of the cancers in the
group that participated screening) in the present work is at the
same level as in many previous works (Peeters et al, 1989;
Everington et al, 1999; Ernst et al, 2004). This indicates that the
quality of the present screening programme is at an acceptable
level.
In our material, the survival of interval cancers was in-between
the clinical and the screen-detected cancers. Earlier studies have
shown that prognosis of the interval cancers may not differ from
the clinically detected cases (Brekelmans et al 1995; Burrell et al,
1996) or it is intermediate to the screen detected and the clinically
detected cancer groups (Groenendijk et al, 2003). Several studies
have shown that interval cancers form a group of tumours with
aggressive characteristics (Porter et al, 1999; Gilliland et al, 2000).
Besides differences in stage, size and axillary lymph node status
there are other biological differences between the screen-detected,
interval and clinically detected cancers, which may influence the
outcome of the patients. Her-2/neu oncogene amplification
(Anttinen et al, 2003) and high-proliferative activity (Crosier
et al, 1999; Groenendijk et al, 2003) are among characteristics that
are much more frequent in the interval cancers than in the screen-
detected tumours.
While the adjusted effect of screening epoch on survival was not
significant, it is suggestive – it might be significant if the tumour
series was larger. On the other hand, it is worth making the point
that in a larger tumour series, size and node status could be
adjusted in more detail and this might further attenuate the effect
of screening on survival in a multivariate analysis. Statistically
significant differences of survival in the screening era groups
disappeared after multivariate analyses.
We conclude that, as expected, breast cancer stage, tumour size
and axillary lymph node status predict more favourable prognosis
for the screening era patients than for the patients diagnosed
before beginning of the screening mammography. These tradi-
tional prognostic markers are biologically justified and clinically
clearly associated with patient outcome. In the present material
with a long follow-up, we were not able to repeat the recent
unexpected but intriguing finding that detection of cancer by
mammography has independent favourable significance.
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Figure 2 Breast cancer survival of screening period patients with screen
detected cancers (N¼224), interval cancers (N¼99), and clinical cancers
(N¼229).
Table 3 Cox multivariate survival analysis of the breast cancer patients
Characteristic Hazard ratio (95% CI) P-value
Age (per year increased) 1.01 (0.98–1.04) 0.50
Period
Prescreening (1977–1986) Indicator
Screening (1987–1997) 0.82 (0.59–1.12) 0.21
Tumour stage
I Indicator
II 1.72 (1.13–2.64) 0.012
III 1.82 (0.81–4.09) 0.14
X (unknown) 3.26 (1.50–7.10) 0.003
Tumour diameter, cm 1.20 (1.06–1.37) 0.005
Pathologic lymph node status (pN)
pN  Indicator
pN+ 2.62 (1.91–3.61) o0.001
pX (unknown) 2.07 (1.16–3.68) 0.013
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